The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations

被引：17
作者：
Qiu, Jing [1 ]
Sharma, Shikhar [1 ]
Rollins, Robert A. [2 ]
Paul, Thomas A. [1 ]
机构：
[1] Pfizer Worldwide Res & Dev, Oncol R&D, San Diego, CA 92121 USA
[2] Pfizer Worldwide Res & Dev, Oncol R&D, Pearl River, NY 10965 USA
来源：
FUTURE MEDICINAL CHEMISTRY | 2020年 / 12卷 / 15期
关键词：
epigenetic therapy; EZH2; inhibitors; immunotherapy; HISTONE METHYLTRANSFERASE EZH2; GROUP PROTEIN EZH2; REGULATORY T-CELLS; EPIGENETIC REGULATION; GENE EZH2; TARGETING EZH2; THERAPEUTIC TARGET; SOMATIC MUTATIONS; SWI/SNF COMPLEXES; STEM-CELLS;
D O I：
10.4155/fmc-2020-0072
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Immune dysfunction in the tumor microenvironment occurs through epigenetic changes in both tumor cells and immune cells that alter transcriptional programs driving cell fate and cell function. Oncogenic activation of the histone methyltransferase EZH2 mediates gene expression changes, governing tumor immunogenicity as well as differentiation, survival and activation states of immune lineages. Emerging preclinical studies have highlighted the potential for EZH2 inhibitors to reverse epigenetic immune suppression in tumors and combine with immune checkpoint therapies. However, EZH2 activity is essential for the development of lymphoid cells, performing critical immune effector functions within tumors. In this review, we highlight the complexity of EZH2 function in immune regulation which may impact the implementation of combination with immunotherapy agents in clinic.
引用
收藏
页码：1415 / 1430
页数：16
相关论文
共 115 条
  • [1] In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2
    Abd Al Kader, Lamia
    Oka, Takashi
    Takata, Katsuyoshi
    Sun, Xu
    Sato, Hiaki
    Murakami, Ichiro
    Toji, Tomohiro
    Manabe, Akihiro
    Kimura, Hiroshi
    Yoshino, Tadashi
    [J]. VIRCHOWS ARCHIV, 2013, 463 (05) : 697 - 711
  • [2] Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways
    Abou El Hassan, Mohamed
    Huang, Katherine
    Eswara, Manoja B. K.
    Zhao, Michael
    Song, Lan
    Yu, Tao
    Liu, Yu
    Liu, Jeffrey C.
    McCurdy, Sean
    Ma, Anqi
    Wither, Joan
    Jin, Jian
    Zacksenhaus, Eldad
    Wrana, Jeffrey L.
    Bremner, Rod
    [J]. PLOS ONE, 2015, 10 (06):
  • [3] Reversing Time: Ezh1 Deficiency Hastens Definitive Hematopoiesis
    Apostol, April C.
    Beaudin, Anna E.
    [J]. CELL STEM CELL, 2018, 22 (03) : 285 - 287
  • [4] Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells
    Arvey, Aaron
    van der Veeken, Joris
    Samstein, Robert M.
    Feng, Yongqiang
    Stamatoyannopoulos, John A.
    Rudensky, Alexander Y.
    [J]. NATURE IMMUNOLOGY, 2014, 15 (06) : 580 - 587
  • [5] EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
    Bachmann, IM
    Halvorsen, OJ
    Collett, K
    Stefansson, IM
    Straume, O
    Haukaas, SA
    Salvesen, HB
    Otte, AP
    Akslen, LA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) : 268 - 273
  • [6] EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
    Beguelin, Wendy
    Popovic, Relja
    Teater, Matt
    Jiang, Yanwen
    Bunting, Karen L.
    Rosen, Monica
    Shen, Hao
    Yang, Shao Ning
    Wang, Ling
    Ezponda, Teresa
    Martinez-Garcia, Eva
    Zhang, Haikuo
    Zheng, Yupeng
    Verma, Sharad K.
    McCabe, Michael T.
    Ott, Heidi M.
    Van Aller, Glenn S.
    Kruger, Ryan G.
    Liu, Yan
    McHugh, Charles F.
    Scott, David W.
    Chung, Young Rock
    Kelleher, Neil
    Shaknovich, Rita
    Creasy, Caretha L.
    Gascoyne, Randy D.
    Wong, Kwok-Kin
    Cerchietti, Leandro
    Levine, Ross L.
    Abdel-Wahab, Omar
    Licht, Jonathan D.
    Elemento, Olivier
    Melnick, Ari M.
    [J]. CANCER CELL, 2013, 23 (05) : 677 - 692
  • [7] EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
    Adrian P. Bracken
    Diego Pasini
    Maria Capra
    Elena Prosperini
    Elena Colli
    Kristian Helin
    [J]. The EMBO Journal, 2003, 22 (20) : 5323 - 5335
  • [8] Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells
    Bugide, Suresh
    Janostiak, Radoslav
    Wajapeyee, Narendra
    [J]. TRENDS IN CANCER, 2018, 4 (08): : 553 - 566
  • [9] Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells
    Bugide, Suresh
    Green, Michael R.
    Wajapeyee, Narendra
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (15) : E3509 - E3518
  • [10] An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
    Burr, Marian L.
    Sparbier, Christina E.
    Chan, Kah Lok
    Chan, Yih-Chih
    Kersbergen, Ariena
    Lam, Enid Y. N.
    Azidis-Yates, Elizabeth
    Vassiliadis, Dane
    Bell, Charles C.
    Gilan, Omer
    Jackson, Susan
    Tan, Lavinia
    Wong, Stephen Q.
    Hollizeck, Sebastian
    Michalak, Ewa M.
    Siddle, Hannah, V
    McCabe, Michael T.
    Prinjha, Rab K.
    Guerra, Glen R.
    Solomon, Benjamin J.
    Sandhu, Shahneen
    Dawson, Sarah-Jane
    Beavis, Paul A.
    Tothill, Richard W.
    Cullinane, Carleen
    Lehner, Paul J.
    Sutherland, Kate D.
    Dawson, Mark A.
    [J]. CANCER CELL, 2019, 36 (04) : 385 - +
12345678910